To determine the possible molecular mechanism of the hepatoprotective nature of withaferin A in the NAFLD model, we conducted a docking study and our results indicated a strong binding of withaferin A to both LXR-α and FXR, which is a known bile acid nuclear receptor (Figures 6A, B). Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.